Меню
Набор скоро начнётся NCT07306234

Doxycycline vs. Macrolide for MRMP (DOMINO)

Фаза IV С лечением Mycoplasma Pneumoniae Mycoplasma Pneumoniae Pneumonia

Ориентир для пациента и семьи

Простыми словами

Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.

Что изучают
В протоколе указаны: Doxycycline, Azithromycin.
Кому может быть актуально
Состояния в реестре: Mycoplasma Pneumoniae, Mycoplasma Pneumoniae Pneumonia. Базовые параметры: 3 лет — 17 лет · Все.
Что важно проверить
Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
Где проводится
South Korea
Следующий шаг
Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →
Официальное название

Efficacy and Safety of Doxycycline Versus Macrolides for Mycoplasma Pneumoniae Infection in Children (DOMINO): A Protocol for a Multicenter, Randomized, Open-Label, Superiority Trial

Обзор

The goal of this clinical trial is to learn if doxycycline works to treat pneumonia in children. It focuses on children with Mycoplasma pneumoniae infection that may not respond to standard medicines. The main questions it aims to answer are: * Does doxycycline stop fevers faster than azithromycin? * Is doxycycline safe for children, specifically regarding tooth color changes? Researchers will compare doxycycline to azithromycin to see if doxycycline works better to treat this type of pneumonia. Participants will: * Take either doxycycline or azithromycin by mouth for 7 to 14 days. * Check their body temperature to see when their fever goes away. * Visit the hospital to check for any medical problems. * Have their teeth checked for color changes 28 days after starting the medicine.

Вмешательства

  • Препарат Doxycycline
    Intervention Group (Doxycycline): Participants will receive oral doxycycline (4 mg/kg/day divided into 2 doses for weight ≤45 kg; 100 mg BID for weight \>45 kg). The standard treatment duration is 7 days, which may be extended up to 14 days based on clinical response.
  • Препарат Azithromycin
    Control Group (Azithromycin): Participants will receive oral azithromycin according to the standard 5-day regimen (10 mg/kg on Day 1, followed by 5 mg/kg on Days 2-5). Rescue Therapy Protocol: To ensure patient safety, a standardized "rescue therapy" protocol is implemented. Participants in the Control group who fail to demonstrate clinical improvement at the 48-72 hour assessment-defined as persistent fever (≥38.0°C) or clinical deterioration-will be immediately switched to doxycycline. Consis

Первичные конечные точки

  • Defervescence rate [Срок оценки: 72 hours]
Вторичные конечные точки (7)
  • Hospitalization Rate [Срок оценки: Up to 30 days]
  • Length of Hospital Stay [Срок оценки: Up to 30 days]
  • Hospital Readmission Rate [Срок оценки: Up to 30 days]
  • Treatment Failure Rate at Day 7 [Срок оценки: 7 days]
  • Time to Resolution of Respiratory Symptoms [Срок оценки: Up to 30 days]
  • Time to Radiological Resolution of Infiltrates [Срок оценки: Up to 30 days]
  • Incidence of Tooth Discoloration in Children Under 8 Years [Срок оценки: Day 28]

Критерии участия

Критерии включения

  • Age: 3 to 17 years at the time of enrollment.
  • Diagnosis: Clinically diagnosed CAP characterized by respiratory symptoms (e.g., fever, cough, auscultatory findings) and chest X-ray confirming pulmonary infiltrates.
  • Pathogen: Confirmed MP M. pneumoniae infection via PCR OR strongly suspected infection based on clinical features and epidemiological grounds (e.g., outbreaks among classmates, poor response to prior non-macrolide antibiotics).
  • Resistance: Suspected macrolide-resistant M. pneumoniae (MRMP) infection (e.g., during a reported local epidemic of MRMP).
  • Timing: Ability to register and initiate the study drug within 72 hours of symptom onset.

Критерии исключения

  • Prior use of tetracyclines, macrolides, or quinolones for the current illness.
  • Complicated pneumonia (e.g., necrosis, empyema, lung abscess) or severe pneumonia requiring immediate intensive care or exhibiting hypoxia (SpO₂ <90%).
  • Hypersensitivity or contraindications to macrolides or tetracyclines.
  • Severe immunocompromised state or severe underlying lung disease.
  • Severe hepatic impairment (AST/ALT >3x upper limits) or severe renal impairment.

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение
Рандомизированное
Модель
Параллельные группы
Маскирование
Открытое
Основная цель
Лечение

Центры проведения

South Korea · 14 центров
  • Department of Pediatrics, Pusan National University School of Medicine, Pusan National Uni — Busan
  • Department of Pediatrics, Gyeongsang National University College of Medicine, Gyeongsang N — Changwon
  • Department of Pediatrics, Chosun University College of Medicine, Chosun University Hospita — Gwangju
  • Department of Pediatrics, Jeju National University School of Medicine, Jeju National Unive — Jeju City
  • Department of Pediatrics, CHA University School of Medicine, CHA Bundang Medical Center, S — Seongnam
  • Department of Pediatrics, Seoul National University College of Medicine, Seoul National Un — Seongnam
  • Department of Pediatrics, College of Medicine, The Catholic University of Korea, Eunpyeong — Seoul
  • Department of Pediatrics, College of Medicine, The Catholic University of Korea, Seoul St. — Seoul
  • … и ещё 6 центров

Публикации

  • Wormser GP, Dattwyler RJ, Shapiro ED, Halperin JJ, Steere AC, Klempner MS, Krause PJ, Bakken JS, Strle F, Stanek G, Bockenstedt L, Fish D, Dumler JS, Nadelman RB. The clinical assessment, treatment, and prevention of lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis. 2006 Nov 1;43(9):1089-134. PMID 17029130
  • Cummings MM. Copyright and reproduction. Bull Med Libr Assoc. 1973 Jul;61(3):344-5. No abstract available. PMID 4725345
  • Kang DH, Lee JY, Chung JH, Cho JM, Lee SH, Park J, Kim TH, Yoo TK, Lee SW. Comparison of efficacy for erectile function and lower urinary tract symptoms of tadalafil 20 mg on-demand and 5 mg once daily in patients with erectile dysfunction. Int J Clin Pract. 2012 Aug;66(8):813-820. doi: 10.1111/j.1742-1241.2012.02946.x. PMID 22805273
  • Xue H, Xu H, Song X, Chen M, Wang X, Ji M, Wang M. Porous Frustrated Lewis Pairs Catalyst Constructed on Defective Zirconium-Based Metal-Organic Frameworks for Hydrogenation Reactions with H2. Inorg Chem. 2024 Aug 26;63(34):16011-16017. doi: 10.1021/acs.inorgchem.4c02470. Epub 2024 Aug 15. PMID 39145892
  • Guo T, Zamuner F, Ting S, Chen L, Rooper L, Tamayo P, Fakhry C, Gaykalova D, Mehra R. Clinical and genomic characterization of chemoradiation-resistant HPV-positive oropharyngeal squamous cell carcinoma. Front Oncol. 2024 Mar 5;14:1336577. doi: 10.3389/fonc.2024.1336577. eCollection 2024. PMID 38505587
  • Forde E, Humphreys H, Greene CM, Fitzgerald-Hughes D, Devocelle M. Potential of host defense peptide prodrugs as neutrophil elastase-dependent anti-infective agents for cystic fibrosis. Antimicrob Agents Chemother. 2014;58(2):978-85. doi: 10.1128/AAC.01167-13. Epub 2013 Nov 25. PMID 24277028
  • Liu Y. [Lay further emphasis on the cosmetic repair of deep burn wounds in extraordinary regions or caused by uncommon agents]. Zhonghua Shao Shang Za Zhi. 2014 Oct;30(5):389-91. Chinese. PMID 25572886
  • Jiao R, Xue B, Zhang M. A Multiform Optimization Framework for Constrained Multiobjective Optimization. IEEE Trans Cybern. 2023 Aug;53(8):5165-5177. doi: 10.1109/TCYB.2022.3178132. Epub 2023 Jul 18. PMID 35687640

Идентификаторы

NCT: NCT07306234 · DOMINO · KNIH

Первоисточники (государственные реестры)

Открыть это исследование на ClinicalTrials.gov ↗